Business
Ionis announces changes to its board of directors at annual meeting of stockholders
- Joseph Loscalzo, M.D., Ph.D., appointed chairman of the board - Ionis founder and Executive Chairman Stanley T. Crooke, M.D., Ph.D., retires from the board
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"- Joseph Loscalzo, M.D., Ph.D., appointed chairman of the board\n - Ionis founder and Executive Chairman Stanley T. Crooke, M.D., Ph.D., retires from the board\n - Breaux B. Castleman retires from the board\n - Allene M. Diaz appointed to the board\n\n\nCARLSBAD, Calif., June 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board. As previously announced, Ionis founder and Executive Chairman Stanley T. Crooke, M.D., Ph.D., has retired from the board. Breaux B. Castleman has also retired from the board. \n\n \n \n \n \n \n \n\n \nDr. Loscalzo has been on the Ionis board since February 2014, serving on the Nominating, Governance and Review and Science/Medical committees. He is currently Hersey Professor of the Theory and Practice of Medicine, Harvard Medical School and chairman, Department of Medicine and physician-in-chief, Brigham and Women's Hospital. He received his A.B. degree, summa cum laude, his Ph.D. in biochemistry and his M.D. from the University of Pennsylvania. An outstanding cardiovascular scientist, clinician and teacher, he is the recipient of many awards, including the Clinician-Scientist Award, the Distinguished Scientist Award, the Research Achievement Award and the Paul Dudley White Award from the American Heart Association. Dr. Loscalzo is editor-in-chief of Circulation, the journal of the American Heart Association, a senior editor of Harrison's Principles of Internal Medicine, a member of the Advisory Council of the National Heart, Lung and Blood Institute and a member of the Council of Councils of the National Institutes of Health. He has authored more than 1,100 peer-reviewed articles and holds 32 patents for his work in the field of nitric oxide and redox biology. Dr. Loscalzo also serves on the board of directors of Leap Therapeutics, Inc.\nDr. Loscalzo assumes leadership of the board from Dr. Crooke. In December 2020, the company announced that after pioneering RNA-targeted therapeutics and leading the company for more than 30 years, Dr. Crooke would step down as executive chairman to focus on his scientific interests and the nonprofit organization he founded, the n-Lorem Foundation. Dr. Crooke will continue to serve as a...